News | March 24, 2026
Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Call it a major breakthrough for diagnostic imaging
Call it a major breakthrough for diagnostic imaging
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
